7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
*Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birtwistle, J; Bunce, CM; Chipman, JK; Davies, NJ; Green, RM; Hayden, RE; Khanim, FL; Pearce, C; Ride, JP; Schrewe, H; Wake, N | 1 |
1 other study(ies) available for 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Topics: 3-Hydroxysteroid Dehydrogenases; 9,10-Dimethyl-1,2-benzanthracene; Aldo-Keto Reductase Family 1 Member C3; Cell Differentiation; Cell Line, Tumor; DNA Damage; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Glycophorins; Hemoglobins; Humans; Hydroxyprostaglandin Dehydrogenases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Oxidative Stress; Stem Cells | 2009 |